Evaluation of Vitrase as an Adjuvant to Increase Absorption and Dispersion of Other Injected Anesthetics
Information source: ISTA Pharmaceuticals
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Pain
Intervention: Vitrase (ovine hyaluronidase) Lyophilized (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: ISTA Pharmaceuticals Official(s) and/or principal investigator(s):
Lisa R Grillone, PhD, Study Director, Affiliation: ISTA Pharmaceuticals, Inc.
Summary
The purpose of this study is to evaluate Vitrase as an adjuvant to increase absorption and
dispersion of other injected anesthetics
Clinical Details
Official title: Phase IV Post-Approval Evaluation of Vitrase as an Adjuvant to Increase the Absorption and Dispersion of Other Injected Anesthetics for Ophthalmic Surgical Procedures
Study design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment
Primary outcome: To evaluate physician acceptance of efficacy of Vitrase as an adjuvant to increase absorption and dispersion of anesthetics used for ophthalmic surgical procedures
Secondary outcome: To determine physician usage of and satisfaction with Vitrase in the 6200 USP unit vial
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Scheduled for an ophthalmic surgical procedure
Exclusion Criteria:
- Known allergy to bee venom
Locations and Contacts
Cincinnati Eye Institute, Cincinnati, Ohio 45242, United States
Additional Information
Starting date: September 2004
Ending date: January 2005
Last updated: January 15, 2007
|
